The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients
The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients
复制标题
DOI：
10.1002/jso.24742
复制
发表时间：
2017-12-01
影响因子：
2.5
通讯作者：
Gamblin, T. Clark
中科院分区：
文献类型：
--
作者：
Silva, Jack P.;Gorman, Richard A.;Gamblin, T. Clark
简介甲胎蛋白 (AFP) 在肝细胞癌 (HCC) 术后复发监测中具有重要作用。预处理或基线 AFP 的效用仍存在争议。本研究假设基线 AFP 水平升高与 HCC 患者较差的总生存率相关。方法使用国家癌症数据库（2004-2013）识别成年 HCC 患者。根据基线 AFP 测量结果将患者分为以下几组： 阴性 (2000)。主要结果是总生存期（OS），通过对数秩检验进行分析并使用 Kaplan-Meier 方法绘制图表。使用多变量回归模型来确定 OS 的风险比 (HR)。结果 在确定的 41107 名患者中，15809 名 (33.6%) 为阴性。阴性组的中位总生存期最高，其次是边缘组、升高组和高度升高组（28.7 个月 vs 18.9 个月 vs 8.8 个月 vs 3.2 个月；P
IntroductionAlpha-fetoprotein (AFP) has a valuable role in postoperative surveillance for hepatocellular carcinoma (HCC) recurrence. The utility of pretreatment or baseline AFP remains controversial. The present study hypothesized that elevated baseline AFP levels are associated with worse overall survival in HCC patients.MethodsAdult HCC patients were identified using the National Cancer Database (2004-2013). Patients were stratified according to baseline AFP measurements into the following groups: Negative (2000). The primary outcome was overall survival (OS), which was analyzed by log-rank test and graphed using Kaplan-Meier method. Multivariate regression modeling was used to determine hazard ratios (HR) for OS.ResultsOf 41107 patients identified, 15809 (33.6%) were Negative. Median overall survival was highest in the Negative group, followed by Borderline, Elevated, and Highly Elevated (28.7 vs 18.9 vs 8.8 vs 3.2 months; P